Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 4/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.43 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6937210 | 0.85 | MAPT (0.54) | PGRALDH1A1KDM4EMAPTESR1 | |
| SCHEMBL1806400 | 0.82 | PBRM1 (0.49) | ALDH1A1KDM4EMAPTESR1ESR2 | |
| SCHEMBL19996037 | 0.81 | KDM4E (0.49) | ALDH1A1KDM4EMAPTESR1ESR2 | |
| SCHEMBL3368868 | 0.79 | PGR (0.69) | PGRALDH1A1KDM4EMAOAMAOB | |
| SCHEMBL3361527 | 0.78 | PGR (0.55) | PGRALDH1A1KDM4EMAOBCA1 | |
| SCHEMBL13113557 | 0.78 | PGR (0.55) | PGRALDH1A1KDM4EMAPTESR1 | |
| SCHEMBL20951359 | 0.78 | PGR (0.55) | PGRALDH1A1KDM4EMAPTCA9 | |
| SCHEMBL192717 | 0.78 | PGR (0.69) | PGRMAOB | |
| SCHEMBL4420953 | 0.75 | PGR (0.77) | PGRALDH1A1KDM4EMAPTMAOA | |
| SCHEMBL388758 | 0.75 | PGR (0.53) | PGRALDH1A1KDM4ECA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376048-A1 | Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases | CELGENE CORPORATION (US) | 2024-11-14 | — | — | US | disclosed |
| EP-4444697-A1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-118632834-A | Indanyl compounds containing carboxylic acids for the treatment of neurodegenerative diseases | 细胞基因公司 | 2024-09-10 | — | — | CN | disclosed |
| WO-2023107563-A1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107563-A1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2023-06-15 | — | — | WO | disclosed |
| US-8153671-B2 | Heterotetracyclic compounds as TPO mimetics | IRM LLC (BM) | 2012-04-10 | — | — | US | disclosed |
| US-8153671-B2 | Heterotetracyclic compounds as TPO mimetics | IRM LLC (BM) | 2012-04-10 | — | — | US | disclosed |
| US-8153671-B2 | Heterotetracyclic compounds as TPO mimetics | IRM LLC (BM) | 2012-04-10 | — | — | US | disclosed |
| US-8101638-B2 | 6-substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| EP-1910338-B1 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM LLC (BM) | 2010-08-25 | — | — | EP | disclosed |
| US-7319152-B2 | Contraception, hormone replacement therapy, cycle-related symptoms, or benign or malignant neoplastic disease; -methyl-5-(5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)-1H-pyrrole-2-carbonitrile | WYETH (US) | 2008-01-15 | — | — | US | disclosed |
| EP-1613597-B1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20070066628-A1 | 5-Aryl-indan-1-ol and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066637-A1 | 5-Aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066675-A1 | 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-03-22 | — | — | US | disclosed |
| WO-2007009120-A2 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM LLC (BM) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007009120-A2 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM LLC (BM) | 2007-01-18 | — | — | WO | disclosed |
| US-20060205715-A1 | 6-Substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY | 2006-09-14 | — | — | US | disclosed |
| CN-1202077-C | New 2,3-dihydroindene compound | DSM IP PROPERTY NV (NL) | 2005-05-18 | — | — | CN | disclosed |
| CN-1253943-A | New 2,3-dihydroindene compound | HOFFMANN LA ROCHE (CH) | 2000-05-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066628-A1 | 5-Aryl-indan-1-ol and analogs useful as progesterone receptor modulators | PGR, CYP19A1, GNRHR | PGR 1/4885ALDH1A1 346/4885KDM4E 1602/4885 |
| US-20060205715-A1 | 6-Substituted nicotinamide derivatives as opioid receptor antagonists | OPRM1, OPRL1, OPRK1 | PGR 1557/4885ALDH1A1 535/4885KDM4E 3752/4885 |
| US-20070066675-A1 | 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators | PGR, CYP19A1, GNRHR | PGR 1/4885ALDH1A1 449/4885KDM4E 1164/4885 |
| US-20240376048-A1 | Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases | S1PR5, S1PR2, LPAR5 | PGR 1698/4885ALDH1A1 766/4885KDM4E 926/4885 |
| US-20070066637-A1 | 5-Aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators | CYP19A1, PGR, GNRHR | PGR 2/4885ALDH1A1 341/4885KDM4E 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.